Skip to main content

Table 3 Dermatological diagnosis before and after 6-week treatment with SkinCera

From: Potential benefits of oral administration of AMORPHOPHALLUS KONJAC glycosylceramides on skin health – a randomized clinical study

 SkinCera groupPlacebo group
ParameterNumber of subjects with symptomsBefore treatmentAfter 3 weeksAfter 6 weeksNumber of subjects with symptomsBefore treatmentAfter 3 weeksAfter 6 weeks
Dryness81.88 ± 0.990.5 ± 0.75**0.63 ± 0.51**121.33 ± 0.491.58 ± 0.511.67 ± 0.65
Whiteheads/ blackheads101.56 ± 0.721.0 ± 0.861.11 ± 0.78111.91 ± 0.832.46 ± 0.522.55 ± 0.69
Hyperpigmentation211.47 ± 0.771.05 ± 0.521.05 ± 0.40*112.46 ± 0.522.36 ± 0.52.14 ± 0.69
Redness101.7 ± 0.671.2 ± 0.910.6 ± 0.84*51.20 ± 0.441.8 ± 0.44LTF
Lesions111.3 ± 0.481.1 ± 0.870.7 ± 0.8251.4 ± 0.541.8 ± 0.45LTF
Itching101.67 ± 0.50.88 ± 0.780.67 ± 0.86*31.33 ± 0.572.33 ± 0.57LTF
Oilyness121.46 ± 0.520.90 ± 0.830.73 ± 0.78*91.11 ± 0.331.22 ± 0.441.71 ± 0.48*
Roughness71.29 ± 0.480.71 ± 0.750.57 ± 0.78111.91 ± 0.832.27 ± 0.472.36 ± 0.81
Overall261.53 ± 0.660.95 ± 0.76***0.79 ± 0.71***251.67 ± 0.741.98 ± 0.63*2.10 ± 0.75**
  1. The values are the mean in each group; analyzed by one-way ANOVA followed by Dunnet’s t test. The data were statistically significant at *p < 0.05, **p < 0.01, ***p < 0.001 within the group. LTF, Lost to follow-up
  2. 0 (no symptoms) - 1 (mild) - 2 (moderate) - 3 (severe)